News | PET Imaging | August 09, 2018

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients

Knowing the heterogeneity of ER expression throughout the body could help guide treatment

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
FIGURE: Distribution of metastases per patient.

FIGURE: Distribution of metastases per patient. Distribution and 18F-FES uptake of all metastases (n=1,617) in 91 individual patients. Bone (blue), lymph node (green), lung (red), breast (pink), brain (orange) and other (purple) lesions are presented. Patients are categorized based on subgroups derived from the cluster analysis. Credit: H.H. Nienhuis et al., University of Groningen, Groningen, The Netherlands

August 9, 2018 — In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the metastases. However, little is known about ER expression across metastases throughout the body and surrounding normal tissue. Using a positron emission tomography (PET) tracer, researchers in the Netherlands have been able to identify differences in ER expression, which could help guide treatment for metastatic breast cancer patients. The study is featured in The Journal of Nuclear Medicine’s August issue.

According to the American Cancer Society, breast cancer is the most common cancer in American women, except for skin cancers, and it is the second leading cause of cancer death for women (following lung cancer). Currently, the U.S. has more than 3.1 million breast cancer survivors, and American women have a 1 in 8 chance of developing breast cancer.

For the study, researchers used fluorine-18-fluoroestradiol (18F-FES) PET to assess ER expression heterogeneity in 91 patients with metastatic breast cancer. 18F-FES uptake was analyzed in 1,617 metastases, as well as in normal tissue.

“The results showed that approximately 50 percent of the patients had one or more estrogen-receptor negative lesions, while the primary tumor was estrogen-receptor positive,” explained Geke A.P. Hospers, M.D., Ph.D., professor of medical oncology at the University of Groningen in The Netherlands. “This heterogeneity of ER expression is, therefore, really common, and it likely affects treatment outcome.”

A higher uptake was found in bone metastases compared to lymph nodes and lung metastases. In addition, in this largest study so far to examine background 18F-FES uptake in the normal tissue surrounding each organ, background uptake was also found to vary per organ, with uptake highest in the skeleton.

Hospers pointed out, “We concluded that 18F-FES uptake in both tumor and normal tissue uptake is heterogeneous and influenced by the site of metastasis. By using cluster analysis on imaging characteristics and metastatic site, three distinct patterns of patients with ER positive metastatic breast cancer were identified.”

She explained the significance, stating, “ER negative lesions will not respond to endocrine treatment, but other ER positive lesions may. The knowledge of this heterogeneity by means of 18F-FES PET may support future specific treatment of metastasis. For example, one ER negative lesion could be treated by radiotherapy, while the endocrine treatment is continued for the other ER positive lesions. The three distinct patterns in ER positive metastatic breast cancer that we identified with our analysis might be useful for future stratification in intervention studies and optimizing personalized treatment.”

For more information: www.jnm.snmjournals.org

Reference

Nienhuis H.H., van Kruchten M., Elias S.G., et al. “18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.” Journal of Nuclear Medicine, March 1, 2018. doi: 10.2967/jnumed.117.198846

Related Content

Joseph J. Cappello Named Executive Director of Are You Dense Nonprofits
News | Breast Density | February 20, 2019
The boards of Are You Dense Inc. and Are You Dense Advocacy Inc., founded by the late Nancy M. Cappello, Ph.D.,...
Congress Directs FDA to Establish Federal Breast Density Inform Standard
News | Breast Density | February 19, 2019 | Jeff Zagoudis, Associate Editor
As part of a federal spending bill passed late Friday, Congress directed the U.S. Food and Drug Administration (FDA) to...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Densitas Enters Partnership Agreement With TeleMammography Specialists
News | Breast Density | February 14, 2019
Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography...
Hologic Launches Unifi Analytics Business Intelligence Tool
Technology | Analytics Software | February 12, 2019
Hologic Inc. announced the U.S. launch of Unifi Analytics, a business intelligence tool that allows healthcare...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Mount Sinai's Digital 3-D Mammography Van Rolls Into New York City
News | Mammography | February 11, 2019
Mount Sinai Hospital recently launched the Mount Sinai Mobile Mammography Program (MMP), bringing essential breast...
breast density cancer awareness
News | Breast Density | February 08, 2019
Governor Michelle Lujan Grisham has signed breast density inform bill, ...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Oxford University Hospitals Employs Barco Synergi for Multi-disciplinary Cancer Conferences
News | Oncology Diagnostics | February 06, 2019
Oxford University Hospitals (OUH) is trialing clinical collaboration technology from Barco for its Multi-disciplinary...